Common Sense Oncology shared a post on LinkedIn:
“A new comment in Nature Portfolio by Drs. Sam Stevens and Deme Karikios discusses the need to rigorously evaluate outcomes following the decision to allow tumour-agnostic immunotherapy reimbursement in Australia.
This bold policy experiment broadens drug availability, but carries an obligation to learn about patient outcomes, quality use of medicines, equity of access and toxicities so that health systems can serve patients in a way that sensibly balances speed, access and certainty with the best available evidence.”
Title: Realizing the benefits of tumour-agnostic access requires a national health learning system
Authors: Samuel X. Stevens and Deme J. Karikios
Read The Full Article
Other articles about Immunotherapy on OncoDaily.